

33 KB 9-1-09

**IN THE SPECIFICATION:**

Page 33, Line 34 (Currently Amended) (i) to (iii), especially MAb 425 and MAb 225 in murine, chimeric or ~~murine~~ humanized versions or fragments or immunoconjugates (preferably immunocytokines) thereof, in combination with one or more chemotherapeutic agents, preferably cisplatin, gemcitabine or taxol.

Page 34, Line 3 (Currently Amended) (i) to (iii), especially MAb 425 and MAb 225 in murine, chimeric or ~~murine~~ humanized versions or fragments or immunoconjugates (preferably immunocytokines) thereof, in combination with another ErbB antagonist.

Page 34, Line 6 (Currently Amended) (i) to (iii), especially MAb 425 and MAb 225 in murine, chimeric or ~~murine~~ humanized versions or fragments or immunoconjugates (preferably immunocytokines) thereof, in combination with an antibody directed to ErbB-2, preferably Herceptin<sup>®</sup>, or ErbB-3, ErbB-4.

Page 34, Line 10 (Currently Amended) (i) to (iii), especially MAb 425 and MAb 225 in murine, chimeric or ~~murine~~ humanized versions or fragments or immunoconjugates (preferably immunocytokines) thereof, in combination with drugs selected from the following group: